Leadership
Joel Latham
President and Chief Executive OfficerJoel Latham has served as the Chief Executive Officer, President, and Director of Incannex Healthcare Inc. since July 2023. Joel brings more than 20 years of senior management and operations experience in both public and private sectors, under Joel’s leadership, Incannex has advanced, and prioritized multiple therapeutic candidates into clinical-stage development. Previously, he was the CEO and Managing Director of Incannex Australia, where he played a key role in the company’s growth and its successful transition to Nasdaq. Joel has also held senior leadership roles in corporate strategy and global market development at Mars Foods, Tabcorp, and Philip Morris International.
Joseph Swan
Chief Financial Officer
Joseph Swan
Chief Financial OfficerJoseph Swan has served as the Chief Financial Officer and Secretary of Incannex Healthcare Inc. since February 2024, where he oversees financial strategy, reporting, and regulatory compliance. Previously, he was the company’s Treasurer and Controller from July 2023 to February 2024, and served as Head of Finance for Incannex Australia from November 2021 to November 2023. Prior to joining Incannex, Joseph held roles as an audit supervisor at HLB Mann Judd, an Australian accounting and advisory firm, an internal auditor at INPEX Australia, and an analyst at Deloitte Australia. He is a Chartered Accountant and holds a degree in commerce, majoring in accounting, from the University of Western Australia.
Lou Barbato, M.D.
Chief Medical Officer
Lou Barbato, M.D.
Chief Medical OfficerDr. Barbato has served as the Chief Medical Officer of Incannex Healthcare Inc. since October 2024. With more than 25 years of experience in clinical development, regulatory strategy, and global medical affairs, Dr. Barbato brings significant drug development expertise in psychiatric and neurological disorders, contributing to the successful approval and launches of multiple therapeutics, including Marplan® (treatment-resistant depression), Luvox CR (anxiety, OCD), Marinol® (synthetic cannabinoid appetite stimulant, chemotherapy-induced nausea and vomiting) and Gilenya (multiple sclerosis). Dr. Barbato joins Incannex from Jazz Pharmaceuticals, where he served as Global Medical Lead for several clinical-stage therapeutic programs addressing neurological disorders. At Jazz, he led cross-functional teams, with responsibility for global medical strategies working with the FDA, EMA, and PMDA. Prior to joining Jazz, Dr. Barbato served as Global Senior Medical Director at Abbvie, and held leadership roles at Biogen Idec, Novartis, Stiefel Laboratories (GSK), Forest Research Institute, and Solvay Pharmaceuticals, where he contributed to successful U.S. and global product registration and approval of multiple psychiatric, neurologic, and oncologic therapeutics. Dr. Barbato is a Clinical Assistant Professor of Psychiatry and Behavioral Science at Emory University School of Medicine, and has authored or co-authored more than 65 papers and presentations. Dr. Barbato earned his M.D. from St. George’s University School of Medicine and B.S. in Biology at St. Peter’s University.
Lekhram Changoer
Chief Technical Officer
Lekhram Changoer
Chief Technical OfficerLekhram Changoer has served as the Chief Technology Officer of Incannex Healthcare Inc. since July 2023, where he oversees the company's technology strategy and innovation initiatives. Prior to this, he was the Chief Technology Officer of Incannex Australia from June 2022 to November 2023, following the acquisition of APIRx Pharmaceuticals LLC, a company he co-founded. At APIRx, Lekhram served as a Director from January 2019 to August 2022, specializing in cannabinoid-based active pharmaceutical ingredients. Before APIRx, he co-founded AXIM Biotechnologies, an ophthalmologic R&D company, and served as its Chief Technology Officer from 2014 to 2020.
Mark Bleackley, Ph.D.
Chief Scientific Officer
Mark Bleackley, Ph.D.
Chief Scientific OfficerMark Bleackley has served as Incannex’s Chief Scientific Officer since January 2020. With more than two decades of experience in industry and academic research, Mark is responsible for R&D strategy and operations at Incannex, including candidate design, formulation, chemistry, manufacturing and controls (CMC), intellectual property and portfolio development through early clinical safety and efficacy assessment. Prior to joining Incannex, Mark served as a senior scientist overseeing multiple projects at Hexima Limited, with cross-functional responsibility for product design and development. Previously, Mark was a post-doctoral research fellow at La Trobe University, where he currently serves as an Honorary Research Fellow and has co-authored more than 45 peer-reviewed publications. Mark earned his Ph.D. in Genetics and B.Sc. in Cell Biology and Genetics from the University of British Columbia.
Parisa Asvadi, Ph.D.
Vice President, Research and Development
Parisa Asvadi, Ph.D.
Vice President, Research and DevelopmentParisa Asvadi, Ph.D., has served in the position of Vice President, Research and Development since 2023. Parisa is responsible for Incannex regulatory activities with a focus on chemistry, manufacturing and controls (CMC). Parisa has more than twenty years of experience in the formulation, non-clinical and clinical development of biopharmaceutical products. Prior to joining Incannex, Parisa held numerous senior management roles with responsibility for designing and implementing manufacturing, testing, non-clinical and clinical development plans for therapeutic candidates, as well as experience in the development of digital health devices. Parisa has experience in preparation of Investigational New Drug Applications (IND) and Clinical Trial Applications (CTA), as well as Biologics License Application (BLA) and Marketing Authorization Applications (MAA) in the United States, Europe, and Australia. In addition, she has authored and co-authored multiple publications and patents. Parisa received her Ph.D. in antibody engineering from the University of Technology, Sydney.
Natalie May
Head of Clinical Operations
Natalie May
Head of Clinical OperationsNatalie May has served as Head of Clinical Operations since 2024. With more than 20 years of experience in managing clinical research programs in the pharmaceutical, biotechnology and medical device industries, Natalie leads clinical research for Incannex’s product development programs. Prior to joining Incannex, Natalie held the position of senior clinical research manager at Douglas Pharmaceuticals. Previously, Natalie held positions as clinical research manager at Soho Flordis International and Medtronic, as well as clinical monitoring and site management roles at IQVIA and INC Research (Syneos). Natalie earned an MSc in Science Management and a BSc in Biomedical Science from the University of Technology, Sydney.
Board of Directors
Troy Valentine
Board Chair
Troy Valentine
Board ChairTroy Valentine has served as the Chairman of the Board of Directors of Incannex Healthcare Inc. since November 2023 and was Chairman of the Board for Incannex Australia from December 2017 to November 2023. With over 27 years of experience in finance, managerial, and board roles, Troy began his career at Hartley Poynton (now Euroz Hartleys Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000, where he became an Associate Director. He is also a director and co-founder of Alignment Capital Pty Ltd, a boutique corporate advisory firm established in 2014.
Joel Latham
President and Chief Executive Officer
Joel Latham
President and Chief Executive OfficerJoel Latham has served as the Chief Executive Officer, President, and Director of Incannex Healthcare Inc. since July 2023. Joel brings more than 20 years of senior management and operations experience in both public and private sectors, under Joel’s leadership, Incannex has advanced, and prioritized multiple therapeutic candidates into clinical-stage development. Previously, he was the CEO and Managing Director of Incannex Australia, where he played a key role in the company’s growth and its successful transition to Nasdaq. Joel has also held senior leadership roles in corporate strategy and global market development at Mars Foods, Tabcorp, and Philip Morris International.
Peter Widdows
Board Member
Peter Widdows
Board MemberPeter Widdows has served as a Director of Incannex Healthcare Inc. since November 2023, following his role as Director at Incannex Australia from 2018 to November 2023. With extensive experience in global leadership, Peter was the Regional Chief Executive Officer for Australasia and Greater China at H. J. Heinz Company from 2008 to 2010, and earlier, the CEO and Managing Director for Heinz Australia from 2002 to 2008. He also held senior roles at Starkist Foods Inc. in Cincinnati. Peter currently serves as Chairman of Sunny Queen Australia Ltd and as a Non Executive Director of Youi Insurance Holdings Ltd. He is a Fellow Chartered Accountant, bringing deep expertise across finance, strategy, and operations.
George Anastassov, M.D.
Board Member
George Anastassov, M.D.
Board MemberDr. George Anastassov has been a Director of Incannex Healthcare Inc. since November 2023, following his role as Director at Incannex Australia from June 2022 to November 2023. A pioneer in cannabinoid-based therapies, Dr. Anastassov co-developed the world’s first cannabinoid-containing chewing gum delivery system. He co-founded and served as Managing Director of APIRx Pharmaceuticals LLC from 2017 to 2022, playing a pivotal role in the development of Combination Compounds. Previously, he was CEO and co-founder of AXIM Biotechnologies, an ophthalmologic research and development company, from 2014 to 2018.
Robert Clark
Board Member
Robert Clark
Board MemberRobert Clark has been a Director of Incannex Healthcare Inc. since November 2023, having previously held the same position at Incannex Australia from August 2022 to November 2023. He is a seasoned expert in strategic regulatory affairs, boasting over 38 years of extensive regulatory experience in the U.S. and internationally. Mr. Clark spent more than 20 years at Pfizer Inc. and over 10 years at Novo Nordisk. Since May 2012, he has held the role of Vice President, U.S. Regulatory Affairs at Novo Nordisk. Prior to this, he served as Vice President of Worldwide Regulatory Strategy and U.S. Regulatory Affairs at Pfizer from 1992 to 2021.
Subscribe and stay connected
"*" indicates required fields